[144] AEHR TEST SYSTEMS SEC Filing

Rhea-AI Filing Summary

AEHR (AEHR) filed a Form 144 notifying a proposed sale of 2,665 common shares, with an aggregate market value of $66,278, representing part of outstanding shares of 30,006,590. The shares are scheduled for sale on 10/09/2025 on NASDAQ. The filer acquired the shares on 04/18/2023 as compensation from the issuer and reports no sales in the prior three months. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.

Positive

• Disclosure complies with Rule 144 by providing broker, share count, acquisition details, and sale date
• No sales reported in prior 3 months, indicating this is not part of a recent selling pattern

Negative

• Insider liquidity — a sale of 2,665 shares valued at $66,278 could modestly increase free float
• No additional context about the insider's reasons for selling beyond the standard representation

Insights

Securities Compliance Analyst

Form 144 shows an insider proposing a routine small sale under Rule 144.

The filing reports 2,665 common shares acquired as compensation on 04/18/2023 and an intended sale date of 10/09/2025 on NASDAQ. This follows Rule 144 procedural requirements by disclosing broker, share count, and aggregate market value.

Key dependencies are the seller's ongoing compliance with Rule 144 volume, holding-period, and public information conditions; the filing explicitly states no undisclosed material information. Monitor for any subsequent Form 4 or additional 144 notices that would indicate further sales within the next 30–90 days.

Capital Markets Analyst

The sale size is immaterial to company market capitalization but signals insider liquidity.

The disclosed aggregate value of $66,278 is small relative to the issuer's listed outstanding shares (30,006,590), so immediate market impact is unlikely. The broker listed is a standard institutional broker, suggesting a routine market sale rather than a block trade off‑exchange.

Investors may note this as an insider liquidity event without operational implications; watch for timing clustering with other insider filings or material announcements within the coming weeks.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Oppenheimer & Co Inc 85 Broad Street New York NY 10004	2665	66278.00	30006590	10/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	04/18/2023	Compensation	Issuer			2665	04/18/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does AEHR's Form 144 disclose about the planned sale?

It discloses a proposed sale of 2,665 common shares valued at $66,278, intended to be sold on 10/09/2025 on NASDAQ.

When were the shares acquired that are being sold for AEHR?

The shares were acquired as compensation from the issuer on 04/18/2023.

Does the Form 144 report any other sales in the past three months for AEHR?

No; the filing states Nothing to Report for securities sold during the past three months.

Who will execute the sale of AEHR shares?

The filing lists Oppenheimer & Co Inc as the broker with an address at 85 Broad Street, New York, NY.

Does the filing indicate undisclosed material information about AEHR?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.